Cardiome Pharma (NASDAQ: CRME) and Cesca Therapeutics (NASDAQ:KOOL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.
Institutional & Insider Ownership
50.8% of Cardiome Pharma shares are held by institutional investors. Comparatively, 2.6% of Cesca Therapeutics shares are held by institutional investors. 3.9% of Cesca Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This table compares Cardiome Pharma and Cesca Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Cardiome Pharma has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, Cesca Therapeutics has a beta of -1.05, indicating that its share price is 205% less volatile than the S&P 500.
Valuation and Earnings
This table compares Cardiome Pharma and Cesca Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cardiome Pharma||$25.26 million||2.26||-$19.61 million||($0.84)||-1.96|
|Cesca Therapeutics||$14.52 million||2.25||-$29.09 million||($0.81)||-3.70|
Cardiome Pharma has higher revenue and earnings than Cesca Therapeutics. Cesca Therapeutics is trading at a lower price-to-earnings ratio than Cardiome Pharma, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of current ratings for Cardiome Pharma and Cesca Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cardiome Pharma presently has a consensus target price of $7.25, indicating a potential upside of 339.39%. Given Cardiome Pharma’s stronger consensus rating and higher probable upside, equities analysts plainly believe Cardiome Pharma is more favorable than Cesca Therapeutics.
Cardiome Pharma beats Cesca Therapeutics on 9 of the 14 factors compared between the two stocks.
Cardiome Pharma Company Profile
Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD and ESMOCARD LYO (esmolol hydrochloride), a short-acting beta-blocker used to control heart rate in various cardiovascular indications, in select European markets. Cardiome has also licensed TREVYENT, a development-stage drug device combination product that is under development for pulmonary arterial hypertension, in certain regions outside the United States.
Cesca Therapeutics Company Profile
Cesca Therapeutics Inc. is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. The Company focuses on the business of research, development and commercialization of autologous cell-based therapeutics for use in the regenerative medicine industry. The Company’s therapeutic development initiatives focuses on the fields of cardiovascular medicine and orthopedic regeneration. The Company offers a range of products, such as SurgWerks System, CellWerks System, AutoXpress System (AXP), MarrowXpress System (MXP), BioArchive System, and manual bag sets for use in the processing and cryogenic storage of cord blood.
Receive News & Ratings for Cardiome Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma and related companies with MarketBeat.com's FREE daily email newsletter.